1. Dr. John A. Kellum
   a. Welcome
   b. Recap of September 8, 2011 AKI Symposium; Overview of this meeting
   c. Confidentiality disclosure
   d. Renal cell protection device discussion/Ken Hallows potentially interested
2. Dr. Sachin Yende
   a. Animal model ideas
   b. Severe sepsis and risk of major cardiovascular models-before, during and after infection
3. Dr. Paul Palevsky
   a. Proposed ancillary studies along with Steven Weisbord
      i. No funding from VA for biomarker repository with long term follow-up
      ii. Looking for industry funding-estimate of $2 million
   b. Contrast nephropathy
   c. Fluid administration protocol
   d. NAC/Placebo
4. Dr. Zhiyong Peng
   a. Animal data shows evidence of dosing and timing effects of NAC
   b. 3 Aims
      i. PKPD
      ii. Measure iron and host of biomarkers
      iii. Risk prediction model—who would respond to intervention?
      iv. Where are we measuring glutathione?-Rebecca Hughey
      v. Tom Nolin stressed the critical importance of measuring, handling and storing samples.
      vi. What do you do with cysteine?
5. Dr. Raghavan Murugan
   a. Fluid resuscitation
      i. Bolus theory
      ii. Maintenance theory
      iii. Timing and volume of fluids/complications
      iv. Dr. Pinsky asked at what time during the course of treatment do you address the acute injury?
6. Dr. Sandra Kane-Gill
   a. Medication Monitoring systems
   b. TheraDoc/ADE detection
   c. RIFLE criteria; 3 Aims:
      i. Move this into ICU where ADE’s are highest
      ii. Compare pharmacists receiving alerts vs those who don’t; include a checklist
      iii. Compare cost/benefit for identification of ADE’s
7. Dr. Natasha Rogers
   a. Thrombospondin
   b. CD47 and its interaction
   c. Interests are role of CD47 in adaptive immunity; effects of immunosuppressive agents on end; CD47/TSP1 and clinical disease
   d. For a proposed pilot study, looking to collaborate for dialysis patient data.

8. Dr. John A. Kellum
   a. Closing remarks